A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.
   Google Scholar   
Citation:
J. Clin. Oncol. vol 26 (15s) abstr 8080
Year:
2008
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Parents:
None
Children:
884  
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Primary Study
NCCTG-N0426
Secondary Studies:
Phases:
2
Keywords: